Asia · Regional markets · Business Standard

Piramal Pharma soars 15% in weak market on huge volume post Q2 results

Published by Business Standard · India 1 h ago

With H2 typically stronger than H1, Piramal Pharma's management said it is well-positioned to deliver a strong FY performance, supported by healthy order book and encouraging…

Read the full article on Business Standard Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.business-standard.com)

Also worth reading

Tech in Asia

Indian enterprise AI startup QwikBuild raises $2.3m pre-seed

Mint

TCS Out, Jio In! Reliance Jio's listing shakes up India’s rich list: IT major crashes out of top 5 as shares tumble 3.5%

The Business Times

Keppel seeks US$1 billion for Vietnam investments as it joins country’s international financial centre

The Straits Times Business

Ambani’s Jio surges 21% in Mumbai debut after record $3.2 billion India IPO

Business Recorder

Pakistan decides to tighten its AML-CFT regimes

The Edge (Singapour et Malaisie)